Drug resistance of hepatoma cells induced by ATP‑binding cassette transporter G2 by reducing intracellular drug concentration

Li,Yuekao; Ding,Boyue; Liu,Jianghui; Li,Xing; He,Caiyi; Wang,Jing; Liu,Liang

doi:10.3892/etm.2023.11823

Drug resistance of hepatoma cells induced by ATP‑binding cassette transporter G2 by reducing intracellular drug concentration

Authors:
- Yuekao Li
- Boyue Ding
- Jianghui Liu
- Xing Li
- Caiyi He
- Jing Wang
- Liang Liu
View Affiliations

Affiliations: Department of Computed Tomography, Tumor Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Radiotherapy, Tumor Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Flow Cytometry, Tumor Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: February 6, 2023 https://doi.org/10.3892/etm.2023.11823
Article Number: 124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The side effects and drug resistance during chemotherapy seriously affect the outcome of and may lead to the failure of chemotherapy for patients with hepatoma. The aim of the present study was to investigate the association between the expression of ATP‑binding cassette transporter G2 (ABCG2) in hepatoma cells and the drug resistance of hepatoma. An MTT assay was used to determine the half‑maximal inhibitory concentration (IC₅₀) of Adriamycin (ADM) in hepatoma HepG2 cells after treatment with ADM for 24 h. An ADM‑resistant hepatoma cell subline, HepG2/ADM, was generated from the HepG2 hepatoma cell line through a stepwise selection with ADM doses from 0.01 to 0.1 µg/ml. The HepG2/ABCG2 cell line, an ABCG2‑overexpressing hepatoma cell line, was established by transfecting the ABCG2 gene into HepG2 cells. The MTT assay was then used to detect the IC₅₀ of ADM in HepG2/ADM and HepG2/ABCG2 cells after treatment with ADM for 24 h and the resistance index was calculated. The apoptosis, cell cycle and ABCG2 protein expression levels in HepG2/ADM, HepG2/ABCG2 cells, HepG2/PCDNA3.1 and their parental HepG2 cells were detected by flow cytometry. In addition, flow cytometry was used to detect the efflux effect of HepG2/ADM and HepG2/ABCG2 cells after ADM treatment. ABCG2 mRNA expression in cells was detected by reverse transcription‑quantitative PCR. After 3 months of ADM treatment, HepG2/ADM cells grew stably in the cell culture medium containing 0.1 µg/ml ADM and the cells were named HepG2/ADM cells. ABCG2 was overexpressed in HepG2/ABCG2 cells. The IC₅₀ of ADM in HepG2, HepG2/PCDNA3.1, HepG2/ADM and HepG2/ABCG2 cells was 0.72±0.03, 0.74±0.01, 11.17±0.59 and 12.75±0.47 µg/ml, respectively. The cell apoptotic rate of HepG2/ADM and HepG2/ABCG2 cells was not significantly different compared with that of HepG2 and HepG2/PCDNA3.1 cells (P>0.05), but the G0/G1 phase population of the cell cycle decreased and the proliferation index increased significantly (P<0.05). The expression levels of ABCG2 gene and protein in HepG2/ADM and HepG2/ABCG2 cells were significantly higher than those in HepG2 and HepG2/PCDNA3.1 cells (P<0.01), but there was no significant difference between HepG2 and HepG2/PCDNA3.1 cells (P>0.05). The ADM efflux effect of HepG2/ADM and HepG2/ABCG2 cells was significantly higher than that of parental HepG2 and HepG2/PCDNA3.1 cells (P<0.05). Therefore, the present study demonstrated that ABCG2 expression is highly increased in drug‑resistant hepatoma cells and that high expression of ABCG2 is involved in the drug resistance of hepatoma by reducing the intracellular drug concentration.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al: Global, regional, and national cancer incidence, motality, years of life lost, yeas lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–548. 2017.PubMed/NCBI View Article : Google Scholar
2	Ju DY, Hainaut P, Gores GJ, Amadou A, Plymoth A and Roberts LR: A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 16:589–604. 2019.PubMed/NCBI View Article : Google Scholar
3	Choi YH and Yu AM: ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 20:793–807. 2014.PubMed/NCBI View Article : Google Scholar
4	Thomas C and Tampé R: Structural and mechanistic principles of ABC transporters. Ann Rev Biochem. 89:605–636. 2020.PubMed/NCBI View Article : Google Scholar
5	Wang Y, Qin Z, Cai S, Yu L, Hu H and Zeng S: The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol. 17:291–306. 2021.PubMed/NCBI View Article : Google Scholar
6	Hegedus C, Telbisz A, Hegedus T, Sarkadi B and Ozvegy-Laczka C: Lipid regulation of the ABCB1 and ABCG2 multidrug transporters. Adv Cancer Res. 125:97–137. 2015.PubMed/NCBI View Article : Google Scholar
7	To KK, Poon DC, Wei Y, Wang F, Lin G and Fu LW: Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. Biochem Pharmacol. 97:27–37. 2015.PubMed/NCBI View Article : Google Scholar
8	Limniatis G and Georges E: Down-regulation of ABCB1 by collateral sensitivity drugs reverses multidrug resistance and up-regulates enolase I. J Biochem. 172:37–48. 2022.PubMed/NCBI View Article : Google Scholar
9	Kukal S, Guin D, Rawat C, Bora S, Mishra MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, et al: Multidrug efflux transporter ABCG2: expression and regulation. Cell Mol Life Sci. 78:6887–6939. 2021.PubMed/NCBI View Article : Google Scholar
10	Xie ZY, Lv K, Xiong Y and Guo WH: ABCG2-meditated multidrug resistance and tumor-initiating capacity of side population cells from colon cancer. Oncol Res Treat. 37:666–668. 2014.PubMed/NCBI View Article : Google Scholar
11	Kozovska Z, Gabrisova V and Kucerova L: Colon cancer: Cancer stem cells markers, drug resistance and treatment. Biomed Pharmacother. 68:911–916. 2014.PubMed/NCBI View Article : Google Scholar
12	Chen D: Tumor formation and drug resistance properties of human glioblastoma side population cells. Mol Med Rep. 11:4309–4314. 2015.PubMed/NCBI View Article : Google Scholar
13	Wang M, Wang Y and Zhong J: Side population cells and drug resistance in breast cancer. Mol Med Rep. 11:4297–4302. 2015.PubMed/NCBI View Article : Google Scholar
14	Kumar P, Nagarajan A and Uchil PD: Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc. 2018.PubMed/NCBI View Article : Google Scholar
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
16	Motlagh NS, Parvin P, Ghasemi F and Atyabi F: . Fluorescence properties of several chemotherapy drugs: Doxorubicin, paclitaxel and bleomycin. Biomed Opt Express. 25:2400–2406. 2016.PubMed/NCBI View Article : Google Scholar
17	Wu Q, Yang Z, Nie Y, Shi Y and Fan D: Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 347:159–166. 2014.PubMed/NCBI View Article : Google Scholar
18	Lu JF, Pokharel D and Bebawy M: MRP1 and its role in anticancer drug resistance. Drug Metab Rev. 47:406–419. 2015.PubMed/NCBI View Article : Google Scholar
19	Masanek U, Stammler G and Volm M: Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol. 2:37–41. 2002.PubMed/NCBI View Article : Google Scholar
20	Zhang YF, Li XH, Shi YQ, Wu YY, Li N, He Q, Ji Q, Wang RQ, Yang SM and Fang DC: CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53. Oncol Rep. 25:1091–1098. 2011.PubMed/NCBI View Article : Google Scholar
21	Lo YL, Wang W and Ho CT: 7,3',4'-Trihydroxyisoflavone modulates multidrug resistance transporters and induces apoptosis via production of reactive oxygen species. Toxicology. 302:221–232. 2012.PubMed/NCBI View Article : Google Scholar
22	Kunická T and Souček P: Importance of ABCC1 for cancer therapy and prognosis. Drug Metab Rev. 46:325–342. 2014.PubMed/NCBI View Article : Google Scholar
23	Misra R, Das M, Sahoo BS and Sahoo SK: Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation. Int J Pharm. 475:372–384. 2014.PubMed/NCBI View Article : Google Scholar
24	Hsieh MJ, Chen MK, Yu YY, Sheu GT and Chiou HL: Psoralen reverses docetaxel-induced multidrug resistance in A549/D16 human lung cancer cells lines. Phytomedicine. 21:970–977. 2014.PubMed/NCBI View Article : Google Scholar
25	Wu CP, Hsiao SH, Murakami M, Lu YJ, Li YQ, Huang YH, Hung TH, Ambudkar SV and Wu YS: Alpha-mangostin reverses multidrug resistance by attenuating the function of the multidrug resistance-linked ABCG2 transporter. Mol Pharm. 14:2805–2814. 2017.PubMed/NCBI View Article : Google Scholar
26	Murakami M, Ohnuma S, Fukuda M, Chufan EE, Kudoh K, Kanehara K, Sugisawa N, Ishida M, Naitoh T, Shibata H, et al: Synthetic analogs of curcumin modulate the function of multidrug resistance-linked ATP-binding cassette transporter ABCG2. Drug Metab Dispos. 45:1166–1177. 2017.PubMed/NCBI View Article : Google Scholar
27	Fan YF, Zhang W, Zeng L, Lei ZN, Cai CY, Gupta P, Yang DH, Cui Q, Qin ZD, Chen ZS and Trombetta LD: Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Lett. 421:186–198. 2018.PubMed/NCBI View Article : Google Scholar
28	Chen Y, Bieber MM and Teng NN: Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Mol Carcinog. 53:625–634. 2014.PubMed/NCBI View Article : Google Scholar
29	Sodani K, Tiwari AK, Singh S, Patel A, Xiao ZJ, Chen JJ, Sun YL, Talele TT and Chen ZS: GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol. 83:1613–1622. 2012.PubMed/NCBI View Article : Google Scholar
30	Lepper ER, Nooter K, Verweij J, Acharya MR, Figg WD and Sparreboom A: Mechanisms of resistance to anticancer drugs: The role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics. 6:115–138. 2005.PubMed/NCBI View Article : Google Scholar
31	Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT and Chen ZS: Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem Pharmacol. 89:52–61. 2014.PubMed/NCBI View Article : Google Scholar
32	Rosenfeldt MT, Bell LA, Long JS, O'Prey J, Nixon C, Roberts F, Dufès C and Ryan KM: E2F1 drives chemotherapeutic drug resistance via ABCG2. Oncogene. 33:4164–4172. 2014.PubMed/NCBI View Article : Google Scholar
33	Nakanishi T and Ross DD: Breast cancer resistance protein (BCRP/ABCG2): Its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 31:73–99. 2012.PubMed/NCBI View Article : Google Scholar
34	Yousaf M and Ali M: Modulation of ABCG2 surface expression by Rab5 and Rab21 to overcome multidrug resistance in cancer cells. Xenobiotica. 50:988–996. 2020.PubMed/NCBI View Article : Google Scholar
35	Kokubo S, Ohnuma S, Murakami M, Kikuchi H, Funayama S, Suzuki H, Kajiwara T, Yamamura A, Karasawa H, Sugisawa N, et al: A phenylfurocoumarin derivative reverses ABCG2-mediated multidrug resistance in vitro and in vivo. Int J Mol Sci. 22(12502)2021.PubMed/NCBI View Article : Google Scholar
36	Mioč M, Telbisz Á, Radman K, Bertoša B, Šumanovac T, Sarkadi B and Kralj M: Interaction of crown ethers with the ABCG2 transporter and their implication for multidrug resistance reversal. Histochem Cell Biol. 158:261–277. 2022.PubMed/NCBI View Article : Google Scholar
37	Ma Y, Guo Z, Fan C, Chen J, Xu S and Liu Z: Rationally screened and designed ABCG2-binding aptamers for targeting cancer stem cells and reversing multidrug resistance. Anal Chem. 94:7375–7382. 2022.PubMed/NCBI View Article : Google Scholar
38	Zattoni IF, Delabio LC, Dutra JP, Kita DH, Scheiffer G, Hembecker M, Pereira GDS, Moure VR and Valdameri G: Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. Eur J Med Chem. 237(114346)2022.PubMed/NCBI View Article : Google Scholar
39	Zhang QH, Dou HT, Xu P, Zhuang SC and Liu PS: Tumor recurrence and drug resistance properties of side population cells in high grade ovary cancer. Drug Res (Stuttg). 65:153–157. 2015.PubMed/NCBI View Article : Google Scholar
40	Britton KM, Eyre R, Harvey IJ, Stemke-Hale K, Browell D, Lennard TWJ and Meeson AP: . Breast cancer, side population cells and ABCG2 expression. Cancer Lett. 323:97–105. 2012.PubMed/NCBI View Article : Google Scholar
41	Tandia M, Mhiri A, Paule B, Saffroy R, Cailliez V, Noé G, Farinotti R and Bonhomme-Faivre L: Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): Monocentric study. Cancer Chemother Pharmacol. 79:759–766. 2017.PubMed/NCBI View Article : Google Scholar
42	Zhang H, Zhang YK, Wang YJ, Kathawala RJ, Patel A, Zhu H, Sodani K, Talele TT, Ambudkar SV, Chen ZS and Fu LW: WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells. Cancer Sci. 105:1071–1078. 2014.PubMed/NCBI View Article : Google Scholar
43	Wang XK, To KK, Huang LY, Xu JH, Yang K, Wang F, Huang ZC, Ye S and Fu LW: Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Oncotarget. 5:11971–11985. 2014.PubMed/NCBI View Article : Google Scholar
44	Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ and Fu LW: Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 279:74–83. 2009.PubMed/NCBI View Article : Google Scholar
45	Jing W, Zhou M, Chen R, Ye X, Li W, Su X, Luo J, Wang Z and Peng S: In vitro and ex vivo anti-tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2-overexpressing leukemia cells. Oncol Rep. 45:1142–1152. 2021.PubMed/NCBI View Article : Google Scholar